Pradaxa vs Xarelto
Side-by-side cost comparison based on Medicare Part D data
Pradaxa
Dabigatran
Manufactured by Boehringer Ingelheim
Xarelto
Rivaroxaban
Manufactured by Janssen
Pradaxa costs 44% less per claim than Xarelto ($180.00 vs $321.00). A generic version of Pradaxa is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Pradaxa | Xarelto |
|---|---|---|
| Avg Cost Per Claim | $180.00 | $321.00 |
| Total Medicare Spending | $876.0M | $5.0B |
| Total Beneficiaries | 580,000 | 1,920,000 |
| Total Claims | 4,860,000 | 15,680,000 |
| Annual Cost/Patient | $1,510.00 | $2,624.00 |
| Year-over-Year Change | -9.8% | -1.2% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Boehringer Ingelheim | Janssen |
| Condition | Blood Clots | Blood Clots |
| Generic Name | Dabigatran | Rivaroxaban |
Pradaxa vs Xarelto: What the Data Shows
Pradaxa (Dabigatran) and Xarelto (Rivaroxaban) are both used to treat blood clots. Based on Medicare Part D data, Pradaxa costs $180.00 per claim, which is 44% less than Xarelto at $321.00 per claim.
Medicare spent $876.0M on Pradaxa and $5.0B on Xarelto. In terms of patient reach, Xarelto serves more beneficiaries (1,920,000 vs 580,000).
Year-over-year spending changed -9.8% for Pradaxa and -1.2% for Xarelto.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Pradaxa is cheaper at $180.00 per claim, compared to $321.00 for Xarelto. That makes Pradaxa about 44% less expensive per claim based on Medicare Part D data.
Yes, both Pradaxa and Xarelto are used to treat blood clots. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Dabigatran and generic Rivaroxaban can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $876.0M on Pradaxa covering 580,000 beneficiaries, and $5.0B on Xarelto covering 1,920,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.